Last reviewed · How we verify

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — Portfolio Competitive Intelligence Brief

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Matching Placebo to Fidaxomicin Matching Placebo to Fidaxomicin phase 3 Infectious Disease
PAR-101/OPT-80 PAR-101/OPT-80 phase 3 Non-systemic antibiotic; bacterial RNA polymerase inhibitor Bacterial RNA polymerase (C. difficile) Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA):

Cite this brief

Drug Landscape (2026). Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/optimer-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa. Accessed 2026-05-16.

Related